港股异动 | 山东新华制药股份(00719)涨超4% 利丙双卡因乳膏获批上市

智通财经11-25

智通财经APP获悉，山东新华制药股份(00719)涨超4%，截至发稿，涨4.14%，报7.05港元，成交额1935.58万港元。

消息面上，11月24日，据中国国家药品监督管理局(NMPA)官网最新显示，山东新华制药股份有限公司按注册分类4类申报的利丙双卡因乳膏获批上市，视同过评。公开资料显示，利丙双卡因乳膏是利丙双卡因乳膏是利多卡因和丙胺卡因的复合制剂，主要用于正常完整皮肤的局部麻醉和生殖器粘膜浅表手术和浸润麻醉的预处理，与传统麻醉药物相比具有便利、安全性高和无依赖性等优点。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2586482754?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-25 11:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586482754","market":"fut","top_or_hot":-1,"title":"港股异动 | 山东新华制药股份(00719)涨超4% 利丙双卡因乳膏获批上市","media":"智通财经","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/00719\">山东新华制药股份</a>(00719)涨超4%，截至发稿，涨4.14%，报7.05港元，成交额1935.58万港元。</p><p>消息面上，11月24日，据中国国家药品监督管理局(NMPA)官网最新显示，山东<a href=\"https://laohu8.com/S/000756\">新华制药</a>股份有限公司按注册分类4类申报的利丙双卡因乳膏获批上市，视同过评。公开资料显示，利丙双卡因乳膏是利丙双卡因乳膏是利多卡因和丙胺卡因的复合制剂，主要用于正常完整皮肤的局部麻醉和生殖器粘膜浅表手术和浸润麻醉的预处理，与传统麻醉药物相比具有便利、安全性高和无依赖性等优点。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 山东新华制药股份(00719)涨超4% 利丙双卡因乳膏获批上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 山东新华制药股份(00719)涨超4% 利丙双卡因乳膏获批上市\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2025-11-25 11:15</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/00719\">山东新华制药股份</a>(00719)涨超4%，截至发稿，涨4.14%，报7.05港元，成交额1935.58万港元。</p><p>消息面上，11月24日，据中国国家药品监督管理局(NMPA)官网最新显示，山东<a href=\"https://laohu8.com/S/000756\">新华制药</a>股份有限公司按注册分类4类申报的利丙双卡因乳膏获批上市，视同过评。公开资料显示，利丙双卡因乳膏是利丙双卡因乳膏是利多卡因和丙胺卡因的复合制剂，主要用于正常完整皮肤的局部麻醉和生殖器粘膜浅表手术和浸润麻醉的预处理，与传统麻醉药物相比具有便利、安全性高和无依赖性等优点。</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1373137.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1373137.html","article_id":"2586482754","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586482754","pubTimestamp":1764040537,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，山东新华制药股份(00719)涨超4%，截至发稿，涨4.14%，报7.05港元，成交额1935.58万港元。消息面上，11月24日，据中国国家药品监督管理局(NMPA)官网最新显示，山东新华制药股份有限公司按注册分类4类申报的利丙双卡因乳膏获批上市，视同过评。公开资料显示，利丙双卡因乳膏是利丙双卡因乳膏是利多卡因和丙胺卡因的复合制剂，主要用于正常完整皮肤的局部麻醉和生殖器粘膜浅表手术和浸润麻醉的预处理，与传统麻醉药物相比具有便利、安全性高和无依赖性等优点。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1191":"制药","BK1515":"抗疫概念","00719":"山东新华制药股份"},"translate_title":"Changes in Hong Kong stocks | Shandong Xinhua Pharmaceutical Co., Ltd. (00719) rose more than 4%, riprodicaine cream was approved for listing","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00719":1.5},"content_text":"智通财经APP获悉，山东新华制药股份(00719)涨超4%，截至发稿，涨4.14%，报7.05港元，成交额1935.58万港元。消息面上，11月24日，据中国国家药品监督管理局(NMPA)官网最新显示，山东新华制药股份有限公司按注册分类4类申报的利丙双卡因乳膏获批上市，视同过评。公开资料显示，利丙双卡因乳膏是利丙双卡因乳膏是利多卡因和丙胺卡因的复合制剂，主要用于正常完整皮肤的局部麻醉和生殖器粘膜浅表手术和浸润麻醉的预处理，与传统麻醉药物相比具有便利、安全性高和无依赖性等优点。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2586482754","isCrawlerRequest":true}